COMMUNIQUÉS West-GlobeNewswire

ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:30

MOUNTAIN VIEW, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. [...]

Nuvectra Announces Divesture of NeuroNexus Subsidiary

02/01/2019 - 14:30

PLANO, Texas, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018, to sell [...]

Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:30

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer [...]

Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:07

EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]

Auransa to Present at Biotech Showcase 2019

02/01/2019 - 14:05

PALO ALTO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need, today announced [...]

Leading BioSciences to Present at Biotech Showcase 2019

02/01/2019 - 14:05

CARLSBAD, Ca., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome ™ , today announced that its chief [...]

Allscripts closes previously announced sale of its interests in Netsmart

02/01/2019 - 14:01

CHICAGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) closed the previously announced sale of its interests in Netsmart Technologies, Inc. on December 31, 2018. Additional pro forma financial details [...]

Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:00

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]

Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:00

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference [...]

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US

02/01/2019 - 14:00

Helsinn Group Announces new Permanent J Code for AKYNZEO ® (fosnetupitant and palonosetron) for injection in the US Akynzeo ® for injection received a permanent J code, J1454 , in the US, by the Centers for Medicare and [...]

Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:00

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]

Eidos Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 14:00

SAN FRANCISCO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on [...]

Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009

02/01/2019 - 14:00

First immunogenicity data now expected in mid-2019 CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies [...]

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

02/01/2019 - 14:00

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th [...]

Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria

02/01/2019 - 14:00

-- Primary Efficacy Endpoint of Change in Urinary Oxalate Excretion at Four Weeks -- -- URIROX-2™, Second Pivotal Phase 3 Trial, Initiated in Fourth Quarter of 2018 -- -- URIROX-1™, First Pivotal Phase 3 Trial, [...]

Ceapro Inc. to Present at Biotech Showcase™ 2019

02/01/2019 - 14:00

Presentation with live audio webcast Tuesday, January 8, 2019 at 2:00 PM PST EDMONTON, Alberta, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. ( TSX-V: CZO) (“Ceapro” or the “Company”) , a growth-stage biotechnology [...]

Sharecare to present at J.P. Morgan Healthcare Conference for sixth consecutive year

02/01/2019 - 14:00

ATLANTA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sharecare, the digital health company helping people manage all their health in one place, today announced it will present at the 37th annual J.P. Morgan Healthcare Conference [...]

Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

02/01/2019 - 14:00

Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our [...]

Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer

02/01/2019 - 14:00

Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programs Dermavant plans to initiate Phase 3 clinical program for [...]